SCHEDULE: Citadel Discloses 9.99% Stake in BriaCell Therapeutics

Citadel and its affiliates, including Kenneth Griffin, have reported a beneficial ownership of 9.99% in BriaCell Therapeutics Corp. common shares.

Summary

• Citadel Advisors LLC, Citadel Advisors Holdings LP, Citadel GP LLC, Citadel Securities LLC, Citadel Securities Group LP, Citadel Securities GP LLC, and Kenneth Griffin (collectively, the "Reporting Persons") have filed a Schedule 13G.
• The filing discloses beneficial ownership of BriaCell Therapeutics Corp. common shares, no par value per share.
• Kenneth Griffin, through various Citadel entities, beneficially owns 717,198 shares, representing 9.99% of the company's outstanding common shares.
• Citadel Advisors LLC, Citadel Advisors Holdings LP, and Citadel GP LLC each beneficially own 716,699 shares, representing 9.98% of the outstanding shares.
• Citadel Securities LLC, Citadel Securities Group LP, and Citadel Securities GP LLC each beneficially own 499 shares, representing 0.0% of the outstanding shares.
• The calculation of ownership is based on 7,179,163 total shares outstanding.
• This total includes 6,211,436 shares outstanding as of January 15, 2026, 657,096 shares issued from warrant exercises, and 310,631 shares issuable from warrants.
• The warrants are subject to a limitation preventing exercise if it would result in beneficial ownership exceeding 9.99% of the shares outstanding immediately after exercise.
• The shares were not acquired for the purpose of changing or influencing control of BriaCell Therapeutics Corp., nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: The disclosure of a significant 9.99% beneficial ownership by Citadel and Kenneth Griffin in BriaCell Therapeutics Corp. is generally viewed positively as it signals confidence from a major institutional investor. This can attract further market attention and potentially stabilize the stock, although the filing itself is a passive disclosure rather than an active endorsement or operational update.

Positives

• A significant stake (9.99%) by a prominent institutional investor like Citadel may signal confidence in BriaCell Therapeutics Corp.'s long-term prospects.
• The investment by a sophisticated financial entity could attract further institutional interest and potentially increase market liquidity for the company's shares.

Risks

• The filing mentions warrants that limit exercise if beneficial ownership exceeds 9.99%, which could cap potential further accumulation by Citadel through these specific instruments.
• The concentration of a significant portion of shares (9.99%) with one institutional investor group could lead to increased volatility if that investor decides to significantly alter its position.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from BriaCell Therapeutics Corp. regarding its future outlook.

Industry Context

This filing indicates a significant investment by a major hedge fund in a publicly traded company, which is a common occurrence in the financial markets. Such disclosures provide transparency regarding large institutional holdings, which can influence market perception and trading activity for the specific stock. The acquisition of a near 10% stake by a prominent firm like Citadel can be interpreted as a vote of confidence in the company's potential within the therapeutics sector.

Related Party Transactions

• The filing details the hierarchical relationship between the various Citadel entities (Citadel Advisors LLC, Citadel Advisors Holdings LP, Citadel GP LLC, Citadel Securities LLC, Citadel Securities Group LP, Citadel Securities GP LLC) and Kenneth Griffin, who collectively report beneficial ownership.
• Shares were issued to affiliates of the reporting persons upon voluntary exercise of warrants.
• Additional shares are issuable upon conversion of warrants held by affiliates of the reporting persons.

Stakeholder Impact

• Shareholders: May view the significant institutional investment as a positive signal, potentially increasing confidence and attracting more investors.
• Company Management: Could see this as validation of their strategy and potentially benefit from increased market liquidity and attention.
• Creditors: No direct impact mentioned, but increased investor confidence could indirectly improve the company's financial standing.

Next Steps

• BriaCell Therapeutics Corp. will continue its operations and strategic initiatives.
• Citadel and its affiliates will continue to hold or may adjust their position in BriaCell Therapeutics Corp. shares based on market conditions and their investment strategy.

Key Dates

Recommendation

The filing is a disclosure of a significant institutional stake, which is generally a positive signal. However, it does not provide new operational or financial performance data for BriaCell Therapeutics Corp. that would warrant a 'buy' or 'sell' recommendation. The presence of a major investor like Citadel could provide some stability or positive sentiment, suggesting a 'hold' position for existing investors while awaiting further company-specific news. New investors might consider it a positive indicator for further due diligence.

Keywords

BriaCell Therapeutics Corp., Citadel, Kenneth Griffin, Schedule 13G, Beneficial Ownership, Common Shares, Institutional Investor, Warrants, SEC Filing, Therapeutics, Biopharma